These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 38233752)
1. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma. Liu W; Du Q; Mei T; Wang J; Huang D; Qin T BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752 [TBL] [Abstract][Full Text] [Related]
2. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target. Li Y; Yang W; Liu C; Zhou S; Liu X; Zhang T; Wu L; Li X; Zhang J; Chang E Int Immunopharmacol; 2024 May; 132():111918. PubMed ID: 38537539 [TBL] [Abstract][Full Text] [Related]
3. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with Zhang YH; Liu XS; Gao Y; Yuan LL; Huang ZM; Zhang Y; Liu ZY; Yang Y; Liu XY; Ke CB; Pei ZJ Lung Cancer; 2024 Feb; 188():107449. PubMed ID: 38184958 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of SFXN1 indicates poor prognosis and promotes tumor progression in lung adenocarcinoma. Chen L; Kang Y; Jiang Y; You J; Huang C; Xu X; Chen F Pathol Res Pract; 2022 Sep; 237():154031. PubMed ID: 35878532 [TBL] [Abstract][Full Text] [Related]
5. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma. Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064 [TBL] [Abstract][Full Text] [Related]
6. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma. Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014 [TBL] [Abstract][Full Text] [Related]
8. ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma. Yang W; Chen K; Yu Q; Liao R; He H; Peng Y; Yang Z; Zhang X Cancer Med; 2023 Jul; 12(13):14820-14832. PubMed ID: 37162299 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related]
10. Sideroflexin1 as a novel tumor marker independently predicts survival in lung adenocarcinoma. Chen Q; Wang R; Zhang J; Zhou L Transl Cancer Res; 2019 Aug; 8(4):1170-1178. PubMed ID: 35116859 [TBL] [Abstract][Full Text] [Related]
11. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates. Fan K; Zhang BH; Han D; Sun YC BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma. Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698 [TBL] [Abstract][Full Text] [Related]
13. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma. Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482 [TBL] [Abstract][Full Text] [Related]
14. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma. Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X Front Immunol; 2023; 14():1070953. PubMed ID: 37334367 [TBL] [Abstract][Full Text] [Related]
15. High Expression of Chen Y; Zhou M; Gu X; Wang L; Wang C Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Cell Death Index for Lung Adenocarcinoma: A Comprehensive Transcriptome-Based Analysis of Twelve Programmed Cell Death Pattern Genes. Chen F; Ma J; Hu S; Wu C; Chen S; Lin J Front Biosci (Landmark Ed); 2024 Apr; 29(4):135. PubMed ID: 38682187 [TBL] [Abstract][Full Text] [Related]
17. Development of a copper metabolism-related gene signature in lung adenocarcinoma. Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S Front Immunol; 2022; 13():1040668. PubMed ID: 36524120 [TBL] [Abstract][Full Text] [Related]
18. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma. Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801 [TBL] [Abstract][Full Text] [Related]
19. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches. Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S PeerJ; 2023; 11():e16166. PubMed ID: 37790630 [TBL] [Abstract][Full Text] [Related]
20. T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing. Zhang J; Liu X; Huang Z; Wu C; Zhang F; Han A; Stalin A; Lu S; Guo S; Huang J; Liu P; Shi R; Zhai Y; Chen M; Zhou W; Bai M; Wu J Comput Biol Med; 2023 Jan; 152():106460. PubMed ID: 36565482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]